Immunotherapies
have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

Registrations are limited and filling fast. First face to face immunology conferences in forever. Covid-19 session from those who shaped our response to the pandemic. National authorities in autoimmunity, inflammation and cancer immunology research all signed up. Can't wait! https://twitter.com/MelbImmunoNet/status/1391607684084862981

MelbImmunoNetwork@MelbImmunoNet

Abstract submissions for the #MIN2021 Winter Symposium are open until 14 May 2021 (AEST). Submit your latest work to contribute to our program (as an oral or poster presenter).

Further details on our website, https://www.melbourneimmunotherapy.org/submissions

Come join our team! We have an exciting opportunity for an experienced animal technician to joint our in-vivo biology group. Applications close soon: https://adposting.cloud.seek.com.au/advertisement/7936fd87-625d-4cbb-bda4-7dc2d6b1d8e6/view

Ready for a new role at the cutting edge of immuno-oncology R&D? Whether it’s changing careers or switching gears, our computational biology team led by @JoeCursons would love to hear from you. Applications close March 24: https://careers.pageuppeople.com/513/ci/en/job/611969/senior-research-officer-computational-biology

Load More...
 
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
OUR APPROACH
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
lab1-webRes
o o
o
THE TEAM
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are